Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around

Description

Summary

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.

Official Title

A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Keywords

Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, rilzabrutinib

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history
  • Participant received at least one course of first-line therapy and had a history of response while on treatment
  • Participant has loss of response, relapse, or steroid dependency

You CAN'T join if...

  • Participants with Secondary ITP
  • Participants with Evans syndrome or history of myelodysplastic syndrome
  • Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy.
  • Participants with history of solid organ transplant
  • Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP
  • Participant received advanced therapy for ITP or was splenectomized
  • Pregnancy or nursing The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations

  • The Lundquist Institute for Biomedical Innovation - Harbor-UCLA Medical Center Site Number: 8400017 accepting new patients
    Torrance California 90502-2006 United States
  • Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) Site Number: 8400005 accepting new patients
    Clovis California 93611 United States
  • University of Southern California (USC) Norris Comprehensive Cancer Center Site Number: 8400015 accepting new patients
    Los Angeles California 90033 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sanofi
Links
LPS18573 Plain Language Results Summary For EU sites click here and navigate to 'Locations and contact points'
ID
NCT07007962
Phase
Phase 3 Immune Thrombocytopenia Research Study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated